`
Wednesday, 28 June 2017

Australia News

  • Cytori, Lorem to commercialize Cytori Cell Therapy

    Australia |  News | By BioSpectrum Bureau | 0 Comment | 05 Nov, 2013

    Singapore: US-based Cytori Therapeutics and China-based Lorem Vascular have formed a partnership to commercialize Cytori Cell Therapy for the cardiovascular, renal and diabetes markets in C...Read more

  • Australian TGA nod for superbug antibiotic

    Australia |  Regulatory | By BioSpectrum Bureau | 0 Comment | 26 Apr, 2013

    Singapore: An effective new antibiotic designed to specifically treat Clostridium difficile-associated diarrhoea will be available to patients in Australia from 14th May 2013. Specialized T...Read more

  • Generon initiates phase I clinical study for F-652 in Australia

    Australia |  News | By BioSpectrum Bureau | 0 Comment | 06 Sep, 2012

    Singapore: Generon (Shanghai)has initiated phase I clinical trial for F-652 in Australia. F-652 is a recombinant protein containing a human interleukin-22 (IL-22) dimer. The current phase I...Read more

  • Aus drug delivery technology gets Chinese patent

    Australia |  News | By BioSpectrum Bureau | 0 Comment | 30 Apr, 2013

    Singapore: Australian drug delivery technology company Imugene has received key Chinese patent application for the company's novel drug delivery technology Linguet. The Chinese application...Read more

  • Post-chemotherapy pain killer trial begins

    Australia |  News | By BioSpectrum Bureau | 0 Comment | 11 Dec, 2012

    Singapore: Spinifex Pharmaceuticals, an Australian pain drug development company, announced that the first set of patients have been treated in its phase II study of EMA401 in chemotherapy...Read more

  • Reva begins trial for bioresorbable scaffold

    Australia |  News | By BioSpectrum Bureau | 0 Comment | 01 Jul, 2013

    Singapore: Australia-based Reva Medical has initiated enrolment of patients for its ReZolve 2 bioresorbable scaffold at multiple clinical sites in Australia and New Zealand. This is in addi...Read more

  • CSL files marketing plea for Privigen in Europe

    Australia |  Regulatory | By BioSpectrum Bureau | 0 Comment | 01 Jun, 2012

    Singapore: Australian company CSL Behring has submitted a variation application to the European Medicines Agency (EMA) for the use of Privigen (immune globulin intravenous [human], 10 perce...Read more

  • Australia registers leukaemia drug in benefit scheme

    Australia |  Regulatory | By BioSpectrum Bureau | 0 Comment | 02 Nov, 2015

    Singapore: A treatment for patients with chronic myeloid leukaemia (CML) and Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) who are resistant or intolerant to curr...Read more

  • Breast cancer market will rise to $3.4 billion by 2021'

    Australia |  News | By BioSpectrum Bureau | 0 Comment | 16 Feb, 2016

    Singapore: The Asia-Pacific (APAC) breast cancer market is set to experience considerable expansion from $1.9 billion in 2014 to $3.4 billion by 2021, at a robust Compound Annual Growth Rat...Read more

  • Aspirin use increases risk of age-related eye disease

    Australia |  News | By BioSpectrum Bureau | 0 Comment | 23 Jan, 2013

    Singapore: Researchers at the Centre for Vision Research from the Westmead Millennium Institute for Medical Research (WMI), a close affiliate of the University of Sydney, have found that re...Read more

  • Orthocell gets patent in Canada

    Australia |  News | By BioSpectrum Bureau | 0 Comment | 14 Dec, 2015

    Singapore: Regenerative medicine company, Orthocell, has been granted a patent in Canada covering the combination of bio-scaffolds and tenocytes, the cells that make up healthy tendons. Th...Read more

  • Bioxyne acquires Vitality

    Australia |  News | By BioSpectrum Bureau | 0 Comment | 22 Feb, 2013

    Singapore: Bioxyne has entered into a non-binding term sheet for the proposed acquisition of 100 percent of the shares and convertible notes in Vitality. Vitality is a marketing distributor...Read more

  • Mid-sized companies are able to achieve much better than big pharma companies in drug development'

    Australia |  Opinion | By Amrita Tejasvi | 0 Comment | 19 Jan, 2016

    Singapore: Australia-based Clinuvel has developed SCENESSE, its proprietary first-in-class photo protective drug, for individuals who are at greatest risk from visible and ultraviolet (UV) ...Read more

  • Aussie firm gets FDA nod to supply cancer antibody in US labs

    Australia |  Regulatory | By BioSpectrum Bureau | 0 Comment | 29 May, 2014

    Singapore: Sienna Cancer Diagnostics, Melbourne-based biotechnology company focused on developing novel in-vitro diagnostic (IVD) tests for cancer, has got USFDA approval for application of...Read more

  • Circadian's new diagnosis tech to be launched in July

    Australia |  News | By BioSpectrum Bureau | 0 Comment | 28 Jun, 2012

    Singapore: A novel technology for aiding the diagnosis of Cancers of Unknown Primary (CUP), by Circadian Technologies, will be commercially launched on July 16, 2012, in Australia, New Zeal...Read more

  • Johnson & Johnson in innovation collaboration with the Queensland Government

    Australia |  News | By BioSpectrum Bureau | 0 Comment | 14 Oct, 2015

    Singapore: The Queensland Government has announced a collaboration with the US pharmaceutical and healthcare giant, Johnson & Johnson, to develop and commercialise healthcare innovation...Read more

  • APAC multiple myeloma market to value $2.8 bn by 2021: Report

    Australia |  Analysis | By BioSpectrum Bureau | 0 Comment | 23 Oct, 2015

    Singapore: The treatment market for multiple myeloma across the Asia-Pacific (APAC) countries of China, India, Japan, and Australia will rise in value from USD1.7 billion in 2014 to USD2.8 ...Read more

  • Aussie anesthetic firm gets patent from 7 nations

    Australia |  News | By BioSpectrum Bureau | 0 Comment | 29 Oct, 2013

    Singapore: Australia-based Drawbridge Pharmaceuticals has been granted patent for its anesthetic formulation Phaxan in the UK, Australia, New Zealand, Hong Kong, Singapore and South Africa....Read more

Survey Box

Will Asia- Pacific healthcare IT market hit the double digit growth in the next five years?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls